We applaud Kakad et al. for their convincing analysis of melatonin’s potential as a treatment for long-term COVID-19 (LC19), emphasizing its pleiotropic effects. Due to oxidative stress and chronic inflammation, LC19 has caused millions of people to suffer from cardiovascular problems such myocarditis and thrombosis. Even while corticosteroids are still a mainstay of treatment, long-term usage of them can have serious adverse effects, such as disruption of metabolism and disturbed sleep. In this letter, we present a novel chronotherapeutic strategy that combines evening melatonin supplementation with morning corticosteroid delivery that is timed to coincide with natural cortisol peaks. This approach seeks to minimize side effects brought on by corticosteroids while maximizing the anti-inflammatory and cardioprotective benefits of both drugs. The cardioprotective, anti-inflammatory, and antioxidant qualities of melatonin enhance corticosteroid treatment, potentially lowering dosages and improving patient results. In order to continue this strategy through coordinated, multi-center trials and guarantee thorough assessment and application of this potential therapeutic paradigm, we also support the creation of a Global LC19 Chronotherapy Consortium.